Abcam, ab173305, Anti-FGFR1 (phospho Y653) antibody [EPR843(N)]

Size: 100µL / 1mL
Rabbit Recombinant Monoclonal FGFR1 phospho Y653 antibody. Suitable for WB, I-ELISA, Dot and reacts with Human samples. Cited in 14 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR843(N),
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:I-ELISA, WB, DotSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:This antibody recognizes FGFR1 (phospho Y653), FGFR2 (phospho Y656), FGFR3 (phospho Y647) and FGFR4 (phospho Y642). Furthermore, ab173305 also reacts with FGFR1 (phospho Y654) and FGFR4 (phospho Y643).

Product details:
This antibody was developed as part of a collaboration between Epitomics and Ira Daar at the National Cancer Institute, NIH.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.35% Sodium citrate, 0.17% Sodium chloride, 0.05% BSA, 0.03% EDTA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
FGFR1 also known as fibroblast growth factor receptor 1 is a protein with a molecular weight of approximately 92 kDa. It is a receptor tyrosine kinase that binds to fibroblast growth factors (FGFs) triggering a cascade of downstream signaling pathways. FGFR1 is widely expressed in various tissues including the brain skeletal muscle and the cardiovascular system. The FGFR1 protein plays an essential role in cellular processes such as proliferation differentiation and survival.
Biological function summary
FGFR1 is significant in embryonic development and tissue repair. It does not function alone; rather it forms a complex with fibroblast growth factors and heparan sulfate proteoglycans facilitating receptor dimerization and autophosphorylation. FGFR1 is involved in bone growth angiogenesis and wound healing processes. The interaction of FGFR1 with these complex factors ensures the precise regulation of these critical physiological events in the body.
Pathways
FGFR1 participates actively in the MAPK/ERK and PI3K/AKT signaling pathways. These pathways are vital for transmitting signals from the cell surface to the DNA in the cell nucleus regulating gene expression and affecting cell cycle progression. FGFR1 works alongside similar proteins like FGFR2 influencing cell fate decisions. By modulating these pathways FGFR1 ensures a proper response to environmental signals which maintains homeostasis and adapts to physiological needs.
FGFR1 is implicated in conditions such as cancer and skeletal dysplasias. Abnormal FGFR1 signaling due to mutations or overexpression can lead to tumorigenesis contributing to the development of cancers like breast and lung cancer. The protein FGFR2 is often evaluated in parallel for similar oncogenic activities. Moreover FGFR1-related dysregulation in bone development can result in skeletal disorders highlighting its importance in both normal physiology and pathological conditions. Anti-FGFR therapies and FGFR1 ELISA tools are being explored to better understand and tackle these diseases.